LONDON (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin.
The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.
Xigduo was developed by the alliance in diabetes therapy between the British company and Bristol-Myers Squibb, the companies said on Wednesday. AstraZeneca will take full control of the unit later this quarter.
Reporting by Paul Sandle; editing by Sarah Young